Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.24 USD
+0.13 (0.27%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $48.26 +0.02 (0.04%) 7:16 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.24 USD
+0.13 (0.27%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $48.26 +0.02 (0.04%) 7:16 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
by Zacks Equity Research
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
by Zacks Equity Research
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
by Zacks Equity Research
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
by Zacks Equity Research
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
by Zacks Equity Research
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
by Zacks Equity Research
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings
by Mark Vickery
Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
by Ahan Chakraborty
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings?
by Zacks Equity Research
Bristol Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx
by Zacks Equity Research
Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.
Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group
by Sheraz Mian
Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study
by Zacks Equity Research
Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.